格隆汇3月26日丨亿胜生物科技(01061.HK)公告，截至2024年12月31日止年度，集团实现营业额约16.698亿港元，较2023年减少3.9%。有关减少乃由于中国监管机构于制药及医疗行业颁布的若干严厉政策和措施。然而，集团预期，当该等政策和措施为人们所熟悉时，随而来的不利局面将得到缓解。尽管营业额减少，集团仍实现纯利约3.07亿港元，同比增加11.6%。每股盈利54.14港仙。
为应对该等挑战，公司须在成本控制与品质保证间取得平衡。创新仍为制药企业发展的核心驱动力。为保持竞争力，公司应：1.增加研发投入以培养创新人才，并加强与公私科研机构和大学的合作；2.注重技术创新，开发具有自主知识产权的产品；及3.探索新的商业模式和运营方式，提升创新效率。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.